Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma
Z. Motahari, J. L. Lepe, M. R. Bautista, C. Hoerig, A. S. Plant-Fox, B. Das, C. D. Fowler, S. N. Magge, D. A. Bota
This study evaluates the efficacy of the MAGMAS inhibitor BT9 in medulloblastoma cell lines and mice, showing in vitro antitumor effects but no survival benefit in vivo.
bioRxiv · Feb 29, 2024Cancer Biology